Oct. 3, 2012ALBUQUERQUE, N.M. – OSO BioPharmaceuticals Manufacturing, LLC, has appointed Alan P. Heim as vice president of human resources.
In his capacity, Heim administers all policies and programs that affect personnel at OsoBio, including issues such as organizational planning; recruitment, hiring and training; employee compensation, performance and benefits; information technology; and labor-related government regulations.
Heim – who has a strong background in organizational leadership and change – brings to OsoBio tremendous experience managing people.
He served for more than 20 years in the U.S. Marine Corps, advancing to the rank of colonel. Among his many tours of duty worldwide included a two-time assignment to the Washington, D.C.-based Joint Operations Staff functioning under then-chairman Gen. Colin Powell.
Upon retiring from the Marines, Heim joined ICN Pharmaceuticals Inc. – now Valeant Pharmaceuticals – as director of organizational planning and development. In 2000, he co-founded Lathian Systems Inc., a software and marketing solutions company for the life-science industry. While there, he helped raise $17 million in venture capital funding, contributed to the company's profitability and grew it to 40 employees. Most recently, Heim served as vice president of human resources for Directed Electronics.
"OsoBio is growing in large part because of the knowledge, expertise, flexibility and responsiveness of our employees," said Milton Boyer, president. "Alan has been key in identifying and recruiting people who embrace and exemplify OsoBio's entrepreneurial culture."
Heim completed a research fellowship at Harvard University, where he studied and wrote about organizational leadership and change. He earned his master's degree in human-resource management from Pepperdine University, and was certified as a Senior Professional of Human Resources.
OsoBio is a contract manufacturing organization (CMO) that specializes in delivering injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products to the pharmaceutical industry. The company offers significant knowledge and experience in late-phase clinical products and successfully taking them to commercialization.
In the history of its Albuquerque, N.M., facility, OsoBio has manufactured more than 250 distinct commercial presentations in every major therapeutic category. The U.S. Drug Enforcement Administration (DEA) has granted OsoBio registrations for Schedule II through V controlled substances.
Responsiveness, attention to detail and clear communication are the hallmarks of OsoBio's client care. Its employees are industry veterans who provide innovative solutions to clients' most difficult projects. To learn more, visit www.OsoBio.com.
Media contact: Karen Stinneford, 919.833.9102